Share on LinkedInShare on LinkedIn

ARTICLE · 12 JANUARY 2026

Class Action Pursued Concerning Safety Defects With GLP-1 Drugs Mounjaro, Trulicity, & Zepbound

An application has been filed in Quebec to obtain authorization to institute a class action concerning the drugs Mounjaro, Trulicity, and Zepbound, alleging that the widely used diabetes and weight-loss medications...

CanadaLitigation, Mediation & Arbitration

An application has been filed in Quebec to obtain authorization to institute a class action concerning the drugs Mounjaro, Trulicity, and Zepbound, alleging that the widely used diabetes and weight-loss medications may expose patients to serious health risks that were not adequately disclosed. On December 23, 2025, Siskinds LLP's Quebec affiliate, Siskinds Desmeules, applied to the Superior Court of Quebec for authorization to bring a case on behalf of Quebec residents who were prescribed and used GLP-1 receptor agonists and experienced serious health problems.

The lawsuit targets Eli Lilly and Company and its Canadian subsidiary, alleging their liability as manufacturers and for other breaches, arguing that they failed to properly warn patients and healthcare providers about serious known or foreseeable risks posed by the active ingredients in the drugs, dulaglutide and tirzepatide. According to the claim, the drugs were marketed as safe and effective without

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from